Drugmakers are having frequent ‘most favored nation’ talks with White Housenews2025-10-31T15:57:39+00:00October 31st, 2025|Endpoints News|
Why are BridgeBio and Alnylam both seeing strong growth for their heart drugs?news2025-10-31T15:34:28+00:00October 31st, 2025|Endpoints News|
Gilead sees cell therapy sales decline in Q3news2025-10-31T01:45:15+00:00October 31st, 2025|Endpoints News|
Novo’s Metsera offer could pose a test for Trump’s FTCnews2025-10-30T19:50:23+00:00October 30th, 2025|Endpoints News|
HHS approves 340B rebate model plans for Merck, Bristol Myers and othersnews2025-10-30T19:47:44+00:00October 30th, 2025|Endpoints News|
Lilly CEO expects more ‘noise’ as Metsera M&A fight beginsnews2025-10-30T19:32:53+00:00October 30th, 2025|Endpoints News|
Merck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’news2025-10-30T18:49:30+00:00October 30th, 2025|Endpoints News|
Bristol Myers Q3 earnings: Cobenfy anxiety, PD-1xVEGF strategy and MFNnews2025-10-30T15:34:04+00:00October 30th, 2025|Endpoints News|
The showdown over Metsera: Pfizer and Novo prepare for a bidding warnews2025-10-30T15:20:13+00:00October 30th, 2025|Endpoints News|
Novo Nordisk’s new CEO is chasing the deals its former leaders wouldn’tnews2025-10-30T15:12:24+00:00October 30th, 2025|Endpoints News|
